The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | The combination of FDG PET plus whole-body MRI for diagnosing multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses a study evaluating the combination of FDG PET and whole-body MRI for diagnosing multiple myeloma (MM). The study reports a 73% agreement between the two techniques and highlights the high accuracy of whole-body MRI at 97%. This preliminary stage sets the groundwork for a larger clinical trial that will incorporate molecular features to contribute to the development of a prognostic index for MM. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
